• TOP 3: MANUEL ELKIN PATARROYO

The vaccine candidate, first developed in
1987, was evaluated in clinical trials carried out by the WHO in Gambia,
Tanzania and Thailand, and had mixed results. In 2009, a comprehensive Cochrane
review assessed the SPf66 as being not efficacious in Africa and Asia, and as
having a low but statistically significant efficacy of 28% in South America.
Today, after more than 33 years of research, the SPf66 malaria vaccine is not
recommended for prophylaxis of malaria and is listed as "inactive" by
the WHO.
No comments:
Post a Comment